Accession Number: | 0001179110-20-009461 |
Date: | 2020-08-28 |
Issuer: | AVADEL PHARMACEUTICALS PLC (AVDL) |
Original Submission Date: |
GLASS GEOFFREY MICHAEL
C/O AVADEL PHARMACEUTICALS PLC
10 EARLSFORT TERRACE
DUBLIN 2, L2 D02 T380
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
ADSS | 2020-08-28 | P | 4,800 | a | $6.78 | 65,700 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|
ID | footnote |
---|---|
f1 | the issuer's "adss" are american depositary shares, with each ads representing one ordinary share, nominal value $0.01 per share, of the issuer; adss may be represented by american depositary receipts. |
f2 | the price reported in column 4 is a weighted average price. these shares were purchased in multiple transactions at prices ranging from $6.54 to $6.93, inclusive. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares purchased at each separate price within the range. |
f3 | includes 27,900 restricted adss granted under the issuer's omnibus incentive compensation plan on 08/01/2018; one-third (1/3) of the adss will vest on each of the first three anniversaries of the grant date. |